Equity Overview
Price & Market Data
Price: $1.04
Daily Change: -$0.05 / 4.81%
Daily Range: $1.04 - $1.12
Market Cap: $91,805,224
Daily Volume: 477,194
Performance Metrics
1 Week: -2.80%
1 Month: -26.76%
3 Months: -31.58%
6 Months: -48.51%
1 Year: 70.60%
YTD: -22.96%
Company Details
Employees: 28
Sector: Health technology
Industry: Biotechnology
Country:
Details
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.